Cargando…

Circulating free DNA in the era of precision oncology: Pre- and post-analytical concerns

Cancer treatment has entered the era of precision medicine, where knowledge of a patient's genetic profile is used to facilitate early diagnosis, drug selection, prognosis, prediction of drug responsiveness, the onset of secondary resistance, and relapse. Circulating free DNA (cfDNA) has emerge...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Jun-Liang, Liang, Zhi-Yong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: KeAi Publishing 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5643833/
https://www.ncbi.nlm.nih.gov/pubmed/29063046
http://dx.doi.org/10.1016/j.cdtm.2016.12.001
_version_ 1783271611408842752
author Lu, Jun-Liang
Liang, Zhi-Yong
author_facet Lu, Jun-Liang
Liang, Zhi-Yong
author_sort Lu, Jun-Liang
collection PubMed
description Cancer treatment has entered the era of precision medicine, where knowledge of a patient's genetic profile is used to facilitate early diagnosis, drug selection, prognosis, prediction of drug responsiveness, the onset of secondary resistance, and relapse. Circulating free DNA (cfDNA) has emerged as an ideal source of genetic information for cancer patients, and numerous studies have explored its validity in various clinical applications. However, clinical implementation of cfDNA-based tests has been slow. In this review, we addressed some of the pre- and post-analytical issues regarding cfDNA tests. First, we summarized the characteristics of cfDNA and reviewed the methods used to identify tumor-derived cfDNA from the pool of total cfDNA. Second, we described the procedures used to extract cfDNA, which have a great impact on representativeness and yield. Finally, we discussed our thoughts on the validation of cfDNA-based tests and the reporting of test results amid drastic limitations.
format Online
Article
Text
id pubmed-5643833
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher KeAi Publishing
record_format MEDLINE/PubMed
spelling pubmed-56438332017-10-23 Circulating free DNA in the era of precision oncology: Pre- and post-analytical concerns Lu, Jun-Liang Liang, Zhi-Yong Chronic Dis Transl Med Perspective Cancer treatment has entered the era of precision medicine, where knowledge of a patient's genetic profile is used to facilitate early diagnosis, drug selection, prognosis, prediction of drug responsiveness, the onset of secondary resistance, and relapse. Circulating free DNA (cfDNA) has emerged as an ideal source of genetic information for cancer patients, and numerous studies have explored its validity in various clinical applications. However, clinical implementation of cfDNA-based tests has been slow. In this review, we addressed some of the pre- and post-analytical issues regarding cfDNA tests. First, we summarized the characteristics of cfDNA and reviewed the methods used to identify tumor-derived cfDNA from the pool of total cfDNA. Second, we described the procedures used to extract cfDNA, which have a great impact on representativeness and yield. Finally, we discussed our thoughts on the validation of cfDNA-based tests and the reporting of test results amid drastic limitations. KeAi Publishing 2016-12-22 /pmc/articles/PMC5643833/ /pubmed/29063046 http://dx.doi.org/10.1016/j.cdtm.2016.12.001 Text en © 2016 Chinese Medical Association. Production and hosting by Elsevier B.V. on behalf of KeAi Communications Co., Ltd. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Perspective
Lu, Jun-Liang
Liang, Zhi-Yong
Circulating free DNA in the era of precision oncology: Pre- and post-analytical concerns
title Circulating free DNA in the era of precision oncology: Pre- and post-analytical concerns
title_full Circulating free DNA in the era of precision oncology: Pre- and post-analytical concerns
title_fullStr Circulating free DNA in the era of precision oncology: Pre- and post-analytical concerns
title_full_unstemmed Circulating free DNA in the era of precision oncology: Pre- and post-analytical concerns
title_short Circulating free DNA in the era of precision oncology: Pre- and post-analytical concerns
title_sort circulating free dna in the era of precision oncology: pre- and post-analytical concerns
topic Perspective
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5643833/
https://www.ncbi.nlm.nih.gov/pubmed/29063046
http://dx.doi.org/10.1016/j.cdtm.2016.12.001
work_keys_str_mv AT lujunliang circulatingfreednaintheeraofprecisiononcologypreandpostanalyticalconcerns
AT liangzhiyong circulatingfreednaintheeraofprecisiononcologypreandpostanalyticalconcerns